Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl transdermal - Hisamitsu

Drug Profile

Fentanyl transdermal - Hisamitsu

Alternative Names: Fentanyl citrate patch - Hisamitsu; Fentanyl citrate transdermal - Hisamitsu; FENTOS; FENTOS TAPE; FENTOS® TAPE; HFT-290

Latest Information Update: 17 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain

Most Recent Events

  • 13 Sep 2019 Hisamitsu Pharmaceutical submits NDA to the Japanese Ministry of Health, Labour and Welfare for Cancer pain (opioid analgesic naive) (Transdermal)
  • 02 Jul 2018 Launched for Cancer pain in Japan (Transdermal, 0.5mg)
  • 02 Jul 2018 Launched for Pain in Japan (Transdermal, 0.5mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top